Jazz Pharmaceuticals plc
JAZZ
$244.96
-$0.89-0.36%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 13.04% | -10.77% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 13.04% | -10.77% | |||
| Cost of Revenue | 20.50% | -14.46% | |||
| Gross Profit | 12.30% | -10.39% | |||
| SG&A Expenses | 10.35% | -15.71% | |||
| Depreciation & Amortization | -1.33% | 1.51% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.01% | -6.43% | |||
| Operating Income | 29.41% | -22.47% | |||
| Income Before Tax | -29.51% | 43.56% | |||
| Income Tax Expenses | 196.72% | 22.91% | |||
| Earnings from Continuing Operations | -34.22% | 44.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -34.22% | 44.06% | |||
| EBIT | 29.41% | -22.47% | |||
| EBITDA | 16.55% | -14.03% | |||
| EPS Basic | -35.57% | 42.11% | |||
| Normalized Basic EPS | -16.25% | 19.46% | |||
| EPS Diluted | -37.25% | 38.13% | |||
| Normalized Diluted EPS | -18.56% | 16.22% | |||
| Average Basic Shares Outstanding | 2.10% | 1.38% | |||
| Average Diluted Shares Outstanding | 4.99% | 4.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||